Adenosine amine congener (Synonyms: ADAC)

Adenosine amine congener (ADAC) is a selective A1 adenosine receptor agonist, can ameliorate noise- and Cisplatin-induced cochlear injury. Adenosine amine congener also has neuroprotective effects[1][2].

Adenosine amine congener can reduce oxidative stress in the noise-exposed cochlea, leading to protection of sensory hair cells. Adenosine amine congener also can reduce cisplatin-induced apoptosis in cochlear tissues, particularly in sensory hair cells and strial marginal cells. The mechanisms of otoprotection by Adenosine amine congener include inhibition of glutamate release via presynaptic A1 receptors and inhibition of voltage-gated Ca2+ channels, which can prevent activation of apoptotic and necrotic cell death pathways[1].

Adenosine amine congener (25-300 μg/kg/day; intraperitoneal injection; daily; for 5 days; male Wistar rats) treatment is most effective in the first 24 hours after noise exposure at doses >50 μg/kg, providing up to 21 dB protection. Adenosine amine congener mitigates noise-induced hearing loss in a dose- and time-dependent manner[1]. Animal Model: Male Wistar rats (8-10 weeks old) treated with noise exposure[1]

[1]. Vlajkovic SM, et al. Adenosine amine congener as a cochlear rescue agent. Biomed Res Int. 2014;2014:841489. [2]. Vlajkovic SM, et al. Adenosine amine congener mitigates noise-induced cochlear injury. Purinergic Signal. 2010 Jun;6(2):273-81.